Glipizide Linked to Highest MACE-4 Risk in Individuals With Type 2 Diabetes
MONDAY, July 28, 2025 -- For individuals with type 2 diabetes (T2D) and moderate cardiovascular risk treated with metformin, the risk for major adverse cardiovascular events is highest for glipizide as a second-line therapy compared with other sulfonylureas and dipeptidyl peptidase 4 inhibitors (DPP4is), according to a study published online July 24 in JAMA Network Open.
Alexander Turchin, M.D., from Brigham and Women's Hospital in Boston, and colleagues conducted a comparative effectiveness research study involving individuals with T2D and moderate cardiovascular risk treated with metformin monotherapy. A total of 48,165 individuals were eligible, of whom 18,147 started glipizide; 14,282 started glimepiride; 1,887 started glyburide; and 13,849 started a DPP4i as a second-line therapy.
The researchers found that during a median follow-up of 37 months, 3,158 individuals (6.6 percent) experienced a 4-point composite of major adverse cardiovascular events (MACE-4; myocardial infarction, ischemic stroke, heart failure hospitalization, or cardiovascular death from any of these conditions). The estimated five-year risks for MACE-4 were 8.1, 8.4, 8.6, and 9.1 percent for DPP4is, glyburide, glimepiride, and glipizide, respectively. The five-year risk ratios (95 percent confidence intervals) of MACE-4 were 1.13 (1.03 to 1.23), 1.07 (0.96 to 1.16), and 1.04 (0.83 to 1.24) for glipizide, glimepiride, and glyburide, respectively, compared with DPP4is.
"While sulfonylureas are popular and affordable diabetes medications, there is a lack of long-term clinical data on how they affect cardiac health in comparison to more neutral alternatives like dipeptidyl peptidase 4 inhibitors," Turchin said in a statement. "Our study underscores the importance of evaluating each drug in a particular pharmacological class on its own merits."
Several authors disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Metabolic Surgery Has Greater Long-Term Benefits Than GLP-1 Receptor Agonists
WEDNESDAY, Oct. 1, 2025 -- People with obesity and type 2 diabetes who undergo metabolic surgery live longer and face fewer serious health problems compared with patients treated...
GLP-1 Receptor Agonists Tied to Reduced Mortality in Patients With Psoriasis
TUESDAY, Sept. 30, 2025 -- Patients with psoriasis treated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have better long-term outcomes compared with those taking...
Nonoptimal Levels of Traditional Risk Factors Almost Universal Before CVD
MONDAY, Sept. 29, 2025 -- Almost all adults have nonoptimal levels of one or more traditional risk factors before being diagnosed with cardiovascular disease (CVD), according to a...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.